Evidence map›Paper›PMID 33705824›Full record

ArticleKidney international2021

The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1

Jennifer Arroyo, Diana Escobar-Zarate, Harrison H Wells, Megan M Constans, Ka Thao, Jessica M Smith, Cynthia J Sieben, Madeline R Martell, Timothy L Kline, Maria V Irazabal and 3 more

Open access · greenAbstract read
In one paragraph

Article in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jennifer ArroyoDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Diana Escobar-ZarateDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Harrison H WellsDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Megan M ConstansDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Ka ThaoDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Jessica M SmithDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Cynthia J SiebenDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Madeline R MartellDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Timothy L KlineDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Maria V IrazabalDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Vicente E TorresDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Katharina HoppDivision of Renal Diseases and Hypertension, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA. Electronic address: katharina.hopp@cuanschutz.edu.
Peter C HarrisDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Harris.peter@mayo.edu.
Mayo Clinic · USUniversity of Colorado Denver · US

Funding

Pilot and FeasibilityP30DK090728 · NIDDK · MAYO CLINIC ROCHESTER · PI TORRES, VICENTE E · 2010 to 2019
$11.8M
ADPKD:Disease Spectrum &Genotype-Phenotype CorrelationsR01DK058816 · NIDDK · MAYO CLINIC ROCHESTER · PI Peter C. Harris · 2001 to 2026
$11.3M
KIDNEY DISEASES RESEARCH TRAINING PROGRAMT32DK007013 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 1986 to 2023
$3.7M
Involvement of Wnt signaling in PKDF31DK105778 · NIDDK · MAYO CLINIC ROCHESTER · PI ARROYO, JENNIFER · 2016 to 2017
$88k
NIDDK NIH HHS F31 DK105778NIDDK NIH HHS P30 DK090728NIDDK NIH HHS R01 DK058816NIDDK NIH HHS T32 DK007013
6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), primarily due to PKD1 or PKD2 mutations, causes progressive kidney cyst development and kidney failure. There is significant intrafamilial variability likely due to the genetic background and environmental/lifestyle factors; variability that can be modeled in PKD mice. Here, we characterized mice homozygous for the PKD1 hypomorphic allele, p.Arg3277Cys (Pkd1

Indexed as

Polycystic Kidney, Autosomal DominantAnimalsGenetic BackgroundKidneyMiceMice, Inbred C57BLMutationTRPP Cation ChannelsTRPP Cation ChannelsADPKDanimal modelsdisease modifiersPKD1preclinical testing

Identifiers

PMID33705824
PMCPMC9107297
OpenAlexW3133872583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.